@article{a9a0052524174e92a3e1f72be65130e6,
title = "Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics",
abstract = "Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.",
keywords = "biologic agents, clinical guidelines for psoriasis, dermatology, guidelines, monoclonal antibodies, psoriasis, skin disease",
author = "Alan Menter and Strober, {Bruce E.} and Kaplan, {Daniel H.} and Dario Kivelevitch and Prater, {Elizabeth Farley} and Benjamin Stoff and Armstrong, {April W.} and Cody Connor and Cordoro, {Kelly M.} and Davis, {Dawn M.R.} and Elewski, {Boni E.} and Gelfand, {Joel M.} and Gordon, {Kenneth B} and Gottlieb, {Alice B.} and Arthur Kavanaugh and Matthew Kiselica and Korman, {Neil J.} and Daniela Kroshinsky and Mark Lebwohl and Leonardi, {Craig L.} and Jason Lichten and Lim, {Henry W.} and Mehta, {Nehal N.} and Paller, {Amy S.} and Parra, {Sylvia L.} and Pathy, {Arun L.} and Rupani, {Reena N.} and Michael Siegel and Wong, {Emily B.} and Wu, {Jashin J.} and Vidhya Hariharan and Elmets, {Craig A.}",
note = "Funding Information: Mark Lebwohl, MD,* served as a consultant for Allergan, Aqua, Arcutis, Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Leo Pharma, Menlo Therapeutics, Mitsubishi Pharma/Neuroderm LTD, Promious/Dr. Reddy, Theravance Biopharma, and Verrica Pharmaceuticals Inc receiving honoraria; as a principal investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Eli Lilly and Company, Incyte Corporation, Janssen Research and Development LLC/Johnson & Johnson, Kadmon Corporation LLC, Leo Pharma, MedImmune/Astra Zeneca, Novartis Pharmaceuticals Corp, Ortho-Dermatologics, Pfizer, Inc, SCIDerm, UCB, and ViDac Pharma receiving grants and/or research funding; and in another role for Corrona, Inc, Facilitation of International Dermatology Education, and the Foundation for Research and Education in Dermatology receiving honoraria. Funding Information: Joel M. Gelfand, MD, MSCE,* served as a consultant for AbbVie, Boehringer Ingelheim, Dermira, Dr Reddy, GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Menlo Therapeutics, Novartis Pharmaceuticals Corp, Pfizer, Inc, Regeneron, Sanofi US Services, and Valeant Pharmaceuticals North America LLC receiving honoraria; as a consultant for BMS receiving fees; as a speaker for the American Academy of Dermatology receiving honoraria; as a speaker and/or faculty educator for CME supported by Eli Lilly and Company receiving fees; as a principal investigator for AbbVie, Celgene, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Novartis Pharmaceuticals Corp, Ortho Dermatologics, Pfizer, Inc, Regeneron, and Sanofi/Sanofi US Services receiving grants and/or research funding; as an investigator for Sanofi receiving grants and/or research funding; as an advisory board member for Sanofi US Services receiving honoraria; as a data safety monitoring board member for Coherus Biosciences and Merck & Co, Inc, receiving honoraria; in another role for the Society for Investigative Dermatology receiving honoraria; in another role for Elsevier, Inc, and SID receiving no compensation; and in another role for Eli Lilly and Company and UCB receiving fees. Funding Information: Alan Menter, MD,* served as a consultant for Abbott Labs, AbbVie, Amgen, Eli Lilly and Company, Galderma USA, Janssen Pharmaceuticals Inc, LEO Pharma US, Menlo Therapeutics, Novartis, Sienna Biopharmaceuticals, and Wyeth Labs receiving honoraria; as a consultant for New Enterprise Associates, Promius Pharma LLC, Spherix Global Insights US, UCB, and Valeant Pharmaceuticals North America receiving fees; as a consultant for Afecta Pharmaceuticals receiving no compensation; as a speaker for Abbott Labs, AbbVie, Amgen, Janssen Biotech, LEO Pharma, US, Pfizer, Inc, Promius Pharma LLC, Sienna Pharmaceuticals, UCB, and Wyeth Labs receiving honoraria; as a principal investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Medimetriks Pharmaceuticals, Inc, Merck & Co, Inc, Novartis Pharmaceutical Corp, and Pfizer, Inc, receiving grant and/or research funding; as an investigator for Eli Lilly and Company and UCB receiving honoraria; investigator for Abbott Labs, Leo Pharma US, and Sienna Biopharmaceutical receiving grants; as an advisory board member for Abbott Labs, AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, LEO Pharma US, Medscape, Pfizer, Inc, and Sienna Biopharmaceuticals, receiving honoraria; as an advisory board member for Amgen receiving grant and/or research funding; as an advisory board member for Afecta Pharmaceuticals receiving no compensation; and as an independent contractor for Prime Education receiving fees. Publisher Copyright: {\textcopyright} 2018 American Academy of Dermatology, Inc.",
year = "2019",
month = apr,
doi = "10.1016/j.jaad.2018.11.057",
language = "English (US)",
volume = "80",
pages = "1029--1072",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",
}